Aptamer-drug conjugates (ApDCs): new trend for cancer precision therapy

doi:10.3969/j.issn.1674-8115.2022.09.003

Abstract

Abstract:

Cancer is a worldwide medical issue that seriously threatens human health. Precision molecular medicine provides a new strategy for cancer theranostics. As excellent targeting recognition molecules and drug delivery platforms, aptamers and aptamer drug-conjugates (ApDCs) have provided a series of useful molecular tools for cancer precision therapy. In this paper, the properties and the selection techniques of aptamers, the construction of ApDCs and their applications to clinical tumor-targeting therapy are reviewed. Additionally, the challenges and perspective of ApDCs in precision molecular medicine for cancers are presented. This review may provide new horizons for molecular-targeted anti-tumor drugs in the therapy of clinical malignant tumors.

Key words: molecular medicine, aptamer, anti-cancer drug, targeted therapy

CLC Number:

R730.5

HAN Yongqi, HAN Da, XIA Qian, JI Dingkun, TAN Weihong. Aptamer-drug conjugates (ApDCs): new trend for cancer precision therapy[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(9): 1176-1181.

TrendMD

References 42

1	SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33.
2	SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33.
3	FERLAY J, COLOMBET M, SOERJOMATARAM I, et al. Cancer statistics for the year 2020: an overview[J]. Int J Cancer, 2021, 149(4): 778-789.
4	潘锋, 张清涵. 科技创新助力肿瘤精准医学发展[J]. 中国医药科学, 2021, 11(24): 1-5.
	PAN F, ZHANG Q H. Technological innovation facilitates the development of precision tumor medicine[J]. Chin Med Pharm, 2021, 11(24): 1-5.
5	谭蔚泓, 徐海燕, 刘艳岚, 等. 分子医学助力健康中国[J]. 肿瘤学杂志, 2021, 27(1): 1-3.
	TAN W H, XU H Y, LIU Y L, et al. Molecular medicine contributes to healthy China[J]. J Chin Oncol, 2021, 27(1): 1-3.
6	KIM D H, SEO J M, SHIN K J, et al. Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy[J]. Biomater Res, 2021, 25(1): 42.
7	XUAN W, PENG Y, DENG Z, et al. A basic insight into aptamer-drug conjugates (ApDCs)[J]. Biomaterials, 2018, 182: 216-226.
8	ELLINGTON A D, SZOSTAK J W. In vitro selection of RNA molecules that bind specific ligands[J]. Nature, 1990, 346(6287): 818-822.
9	TUERK C, GOLD L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase[J]. Science, 1990, 249(4968): 505-510.
10	ZHU G, NIU G, CHEN X. Aptamer-drug conjugates[J]. Bioconjug Chem, 2015, 26(11): 2186-2197.
11	SEFAH K, SHANGGUAN D, XIONG X, et al. Development of DNA aptamers using cell-SELEX[J]. Nat Protoc, 2010, 5(6): 1169-1185.
12	NI S, ZHUO Z, PAN Y, et al. Recent progress in aptamer discoveries and modifications for therapeutic applications[J]. ACS Appl Mater Interfaces, 2021, 13(8): 9500-9519.
13	ZHU G, CHEN X. Aptamer-based targeted therapy[J]. Adv Drug Deliv Rev, 2018, 134: 65-78.
14	SOUNDARARAJAN S, CHEN W, SPICER EK, et al. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells[J]. Cancer Res, 2008, 68(7): 2358-2365.
15	ZHU C, YANG G, GHULAM M, et al. Evolution of multi-functional capillary electrophoresis for high-efficiency selection of aptamers[J]. Biotechnol Adv, 2019, 37(8): 107432.
16	WU Y X, KWON Y J. Aptamers: the “evolution” of SELEX[J]. Methods, 2016, 106: 21-28.
17	BEREZOVSKI M V, MUSHEEV M U, DRABOVICH A P, et al. Non-SELEX: selection of aptamers without intermediate amplification of candidate oligonucleotides[J]. Nat Protoc, 2006, 1(3): 1359-1369.
18	JEONG S, HAN S R, LEE Y J, et al. Selection of RNA aptamers specific to active prostate-specific antigen[J]. Biotechnol Lett, 2010, 32(3): 379-385.
19	YANG X, LI N, GORENSTEIN D G. Strategies for the discovery of therapeutic aptamers[J]. Expert Opin Drug Discov, 2011, 6(1): 75-87.
20	BAGALKOT V, FAROKHZAD O C, LANGER R, et al. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform[J]. Angew Chem Int Ed Engl, 2006, 45(48): 8149-8152.
21	HU Y, DUAN J, ZHAN Q, et al. Novel MUC₁ aptamer selectively delivers cytotoxic agent to cancer cells in vitro[J]. PLoS One, 2012, 7(2): e31970.
22	LIU Z, DUAN J H, SONG Y M, et al. Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro[J]. J Transl Med, 2012, 10: 148.
23	HUANG Y F, SHANGGUAN D, LIU H, et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells[J]. Chembiochem, 2009, 10(5): 862-868.
24	ZHOU F, WANG P, PENG Y, et al. Molecular engineering-based aptamer-drug conjugates with accurate tunability of drug ratios for drug combination targeted cancer therapy[J]. Angew Chem Int Ed Engl, 2019, 58(34): 11661-11665.
25	HE J, PENG T, PENG Y, et al. Molecularly engineering triptolide with aptamers for high specificity and cytotoxicity for triple-negative breast cancer[J]. J Am Chem Soc, 2020, 142(6): 2699-2703.
26	YANG Q, DENG Z, WANG D, et al. Conjugating aptamer and mitomycin C with reductant-responsive linker leading to synergistically enhanced anticancer effect[J]. J Am Chem Soc, 2020, 142(5): 2532-2540.
27	WANG R, ZHU G, MEI L, et al. Automated modular synthesis of aptamer-drug conjugates for targeted drug delivery[J]. J Am Chem Soc, 2014, 136(7): 2731-2734.
28	JIN C, ZHANG H, ZOU J, et al. Floxuridine homomeric oligonucleotides “hitchhike” with albumin in situ for cancer chemotherapy[J]. Angew Chem Int Ed Engl, 2018, 57(29): 8994-8997.
29	XUAN W, XIA Y, LI T, et al. Molecular self-assembly of bioorthogonal aptamer-prodrug conjugate micelles for hydrogen peroxide and pH-independent cancer chemodynamic therapy[J]. J Am Chem Soc, 2020, 142(2): 937-944.
30	YANG Y, HE J, ZHU W, et al. Molecular domino reactor built by automated modular synthesis for cancer treatment[J]. Theranostics, 2020, 10(9): 4030-4041.
31	GAO F, ZHOU J, SUN Y, et al. Programmable repurposing of existing drugs as pharmaceutical elements for the construction of aptamer-drug conjugates[J]. ACS Appl Mater Interfaces, 2021, 13(8): 9457-9463.
32	YANG C, ZHAO H, SUN Y, et al. Programmable manipulation of oligonucleotide-albumin interaction for elongated circulation time[J]. Nucleic Acids Res, 2022, 50(6): 3083-3095.
33	NI X, CASTANARES M, MUKHERJEE A, et al. Nucleic acid aptamers: clinical applications and promising new horizons[J]. Curr Med Chem, 2011, 18(27): 4206-4214.
34	NG E W, SHIMA D T, CALIAS P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease[J]. Nat Rev Drug Discov, 2006, 5(2): 123-132.
35	周灵丽, 叶茂. 核酸适配体介导的肿瘤免疫治疗研究进展[J]. 生物化学与生物物理进展, 2022, 49(6): 1036-1044.
	ZHOU L L, YE M. Research progress of aptamer-mediated tumor immunotherapy[J]. Prog Biochem Biophys, 2022, 49(6): 1036-1044.
36	HARBECK N, PENAULT-LLORCA F, CORTES J, et al. Breast cancer[J]. Nat Rev Dis Prim, 2019, 5(1): 66.
37	YOON S, ARMSTRONG B, HABIB N, et al. Blind SELEX approach identifies RNA aptamers that regulate EMT and inhibit metastasis[J]. Mol Cancer Res, 2017, 15(7): 811-820.
38	PARK J Y, CHO Y L, CHAE J R, et al. Gemcitabine-incorporated G-quadruplex aptamer for targeted drug delivery into pancreas cancer[J]. Mol Ther Nucleic Acids, 2018, 12: 543-553.
39	APTEKAR S, ARORA M, LAWRENCE C L, et al. Selective targeting to glioma with nucleic acid aptamers[J]. PLoS One, 2015, 10(8): e0134957.
40	WU Q, WANG Y, WANG H, et al. DNA aptamers from whole-cell SELEX as new diagnostic agents against glioblastoma multiforme cells[J]. Analyst, 2018, 143(10): 2267-2275.
41	LUO Z, YAN Z, JIN K, et al. Precise glioblastoma targeting by AS1411 aptamer-functionalized poly (L‑γ‑glutamylglutamine)‑paclitaxel nanoconjugates[J]. J Colloid Interface Sci, 2017, 490: 783-796.
42	ZHAO N, PEI S N, QI J, et al. Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia[J]. Biomaterials, 2015, 67: 42-51.

[1]	Jia-ling ZHANG, Feng-chun ZHANG, Ying-chun XU. Research progress in the systemic treatment for breast cancer with brain metastasis [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(5): 671-677.
[2]	XU Kang-li1, MA Ya-ni2, WANG Xiao-jin3, MIAO Yan-yan1, HAN Da1#, TAN Wei-hong1#. Using aptamer of sgc8 for diagnosis of acute leukemia [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(9): 1157-1167.
[3]	LI Chao, MI Jian-qing, WANG Jin. Advances in Philadelphia chromosome-like acute lymphoblastic leukemia [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(9): 1294-1301.
[4]	YANG Yang, LI Dai-rong, LI You-lun, CHEN Yu-han, WAN Qiu, LIU Jing-shu. Evaluation of anti-tuberculosis effect of Mycobacterium tuberculosis polyphosphate kinase 2 aptamer [J]. , 2018, 38(1): 36-.
[5]	ZHANG Lin-yuan, ZHANG Ming, DA Jun. Application of mTOR inhibitor everolimus for the treatment of renal cell carcinoma [J]. , 2016, 36(12): 1812-.
[6]	CHENG Kang, SUN Fu-kang. Role of PI3K/AKT/mTOR signaling pathway in development and progress of pheochromocytoma and its combined targeted therapies [J]. , 2015, 35(1): 137-.
[7]	MIAO Ying, ZHANG Ling-fei, LIANG Sheng, et al. Experimental study on targeting and inhibiting hexokinase 2 by miR-143 for treatment of breast cancer [J]. , 2014, 34(8): 1107-.
[8]	XU Fa-liang, ZHOU Qi, KUANG Yi, et al. Screening of DNA aptamers for recognizing tumor cells by using cell-systematic evolution of ligands by exponential enrichment [J]. , 2013, 33(12): 1684-.
[9]	FU Guo-hui, WANG Ting, SUO Wen-Hao. Progression of targeted therapy of anion exchanger 1 for gastric cancer [J]. , 2012, 32(9): 1155-.
[10]	CHEN Sai-juan, ZHAO Wei-li, ZHANG Xiao-wei, et al. Accelerate the translational research and promote the systems biology study on hematology [J]. , 2012, 32(9): 1234-.
[11]	GU Ai-qin, GAO Zhi-qiang, WANG Hui-min, et al. Clinical analysis of gefitinib in treatment of elderly patients with advanced non-small cell lung cancer [J]. , 2011, 31(3): 305-.
[12]	CHAI Hong, CHEN Ze-quan, YU Yong-li. Research progress of targeted therapy in medullary thyroid carcinoma [J]. , 2011, 31(10): 1470-.